Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jack Scheuer

Internal Medicine Camden, SC Medical Doctor

NPI 1871544403 CMS profile 356851

1344 Haile St, Camden, SC 29020

Open in the dashboard

General payments

$3,740

231 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$6,809 paid to institutions, not to them · program years 2019–2020

Through program year 2025, Jack Scheuer of Camden, SC is reported in the CMS Open Payments database as having received $3,740 across 231 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $6,809 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 86th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $283 3
2021 General $1,213 75
2020 General $965 67
2019 General $1,279 86

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jack Scheuer
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Jack Scheuer were reported at $283. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Jack Scheuer Internal Medicine median Middle half National median
2019 $1,279 $159 $48–$570 $163
2020 $965 $119 $33–$402 $114
2021 $1,213 $135 $37–$521 $132
2022 $0 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $283 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $510 13 payments
  2. AstraZeneca Pharmaceuticals LP $423 28 payments
  3. Pfizer Inc. $356 26 payments
  4. GlaxoSmithKline, LLC. $304 26 payments
  5. Janssen Pharmaceuticals, Inc $283 15 payments
  6. Novo Nordisk Inc $233 11 payments
  7. Amgen Inc. $232 15 payments
  8. Teva Pharmaceuticals USA, Inc. $181 11 payments
  9. Amarin Pharma Inc. $171 14 payments
  10. AbbVie, Inc. $121 13 payments
  11. Other $925 59 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,740 231 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $281 21 payments
  2. XARELTO $261 13 payments
  3. TRELEGY ELLIPTA $256 22 payments
  4. Ozempic $233 11 payments
  5. BOTOX COSMETIC $180 2 payments
  6. AJOVY $169 10 payments
  7. Vascepa $149 12 payments
  8. COLOGUARD $146 5 payments
  9. Repatha $142 9 payments
  10. AIMOVIG $122 8 payments
  11. Other $2,561 196 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 193 drugs

Part D claims

13,448

Median for Internal Medicine: 777

Drug cost

$1,187,780

Median for Internal Medicine: $73,373

Branded share of claims

20.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 255 $214,225
Eliquis Apixaban Brand 281 $156,522
Ozempic Semaglutide Brand 70 $100,211
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 61 $81,824
Trulicity Dulaglutide Brand 29 $42,979
Entresto Sacubitril/Valsartan Brand 46 $42,175
Januvia Sitagliptin Phosphate Brand 27 $30,310
Tivicay Dolutegravir Sodium Brand 12 $28,333
Janumet Sitagliptin Phos/Metformin Hcl Brand 27 $28,153
Xifaxan Rifaximin Brand 12 $26,973

The 10 drugs with the highest cost, of 193 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 86 billing codes

Paid by Medicare

$246,003

Of which drugs: $18,756

Medicare patients

1,047

Average age 76

Services billed

8,516

553 women, 494 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Diabetes 38%
Ischemic heart disease 36%
Chronic kidney disease 29%
Atrial fibrillation 25%
Depression 23%
COPD 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 43 43 $12,412
Vaccine for influenza for injection into muscle 90662 Office 71 71 $5,809
Injection, methylprednisolone acetate, 1 mg J1010 Office 46 2,860 $285

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

231 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record